FLT3 and myeloid sarcoma: Mutations in C‐kit and ETV6 were the most common in MS (6/43, 14.0%), followed by mutations in TET2 (5/43, 11.6%), biallelic CEBPA (4/43, 9.3%), and FLT3‐ITD (4/43, 9.3%).